Stifel starts coverage of Immatics stock with USD 15 target

Published on 10/20/2026 at 12:38 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Second-quarter revenue was USD 10.44 million, below USD 12.42 million estimates. Immatics stock costs EUR 6.30 on October 20, 2026.

Analyst coverage and quarter

Stifel initiated coverage with a USD 15.00 target on October 13, 2026.
Second-quarter revenue reached USD 10.44 million against USD 12.42 million expected.
Immatics stock traded at EUR 6.30 at 12:33 p.m. CEST at Lang & Schwarz on October 20, 2026.

IMTX, NL0015285941, Illustration mit AI erstellt.

Immatics N.V. (ISIN NL0015285941) traded at EUR 6.30 at Lang & Schwarz on October 20, 2026, while the latest analyst catalyst was Stifel's USD 15.00 target. The company had reported second-quarter revenue of USD 10.44 million, below the USD 12.42 million consensus estimate, according to MarketBeat.

Stifel opens a new coverage chapter

Markets Insider reported on October 13, 2026, that Stifel initiated coverage with a Buy rating and a USD 15.00 price target. The note highlighted Immatics' PRAME-HLA approach and its anzu-cel cell therapy program for melanoma.

The target is materially above the current euro quote, but the currencies are different and therefore do not support a direct percentage comparison. The more immediate counterpoint is the latest quarterly performance: MarketBeat reported adjusted earnings per share of minus USD 0.53 against a consensus estimate of minus USD 0.47, alongside the revenue shortfall.

What does the target mean for the pipeline?

Stifel's thesis rests on clinical execution rather than current profitability. The company is advancing T-cell receptor therapies and TCR bispecifics for solid tumors, with anzu-cel positioned as a central melanoma program. The investor-relations page describes Immatics as a precision-targeting biotechnology company focused on PRAME across more than 50 cancers.

Three dates shape the story

On August 18, 2026, Immatics reported second-quarter revenue of USD 10.44 million and adjusted earnings per share of minus USD 0.53, according to Nasdaq. On September 26, 2026, Wall Street Zen raised its rating from sell to hold, as reported by The Stock Observer. On October 13, 2026, Stifel initiated coverage with a USD 15.00 target.

Stock quote and company profile

Immatics is listed on Nasdaq under ticker IMTX and operates in biotechnology. Its market capitalization was USD 1.1 billion as of October 19, 2026, while the 52-week range stood at USD 6.65 to USD 12.41. The latest quarter also showed net income of minus USD 62.49 million and cash of USD 232.46 million for the period ended June 30, 2026.

The stock was trading at EUR 6.30 at Lang & Schwarz on October 20, 2026 at 12:33 p.m. CEST. The further course of trading is shown by the continuously updated real-time quote of Immatics stock.